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Marc C Patterson1,8*, Eugen Mengel2, Frits A Wijburg3, Audrey Muller4, Barbara Schwierin4, Harir Drevon5,
Marie T Vanier6 and Mercé Pineda7Correction
After the publication of this work [1] it was brought to
the authors attention that Figure 1 contained an inver-
sion in the color of the triangles, where yellow which
should be "diagnosis" is said to be "first miglustat use",
and blue which should be " first miglustat use" is said to
be " diagnosis". The correct figure is given below:
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Figure 1 Overview of patient and disease characteristics. We regret any inconvenience that this inaccuracy may have caused.
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